LaderD. Office for National Statistics, UK Omnibus Survey no. 41, Contraception and Sexual Health 2008–09
2.
UK Medical Eligibility for Contraceptive Use, Faculty of Sexual and Reproductive Healthcare, UK. See: http://www.fsrh.org/admin/uploads/UKMEC2009.pdf (last accessed 10 March 2010)
3.
DunsonDB, ColumboB, BairdDD. Changes with age in the level and duration of fertility in the menstrual cycle. Hum Reprod2002;17:1399–403
4.
GlasierA, GebbieAE (eds). Handbook of Family Planning and Reproductive Healthcare 5E, Churchill Livingstone, UK, 2007
5.
Faculty of Family Planning and Reproductive Health Care Guidance. Contraception for women aged over 40 years. J Fam Planning Reprod Healthcare2005;31:51–64
6.
BeralV, HermonC, KayC, HannafordP, DarbyS, ReevesG. Mortality associated with OC use: 25 year follow up of 46,000 women from the RCGP oral contraception study. BMJ1999;318:96–100
7.
HardmanSMR, GebbieAE. Hormonal contraceptive regimens in the perimenopause. Maturitas2009;63:204–12
8.
EdelmanA, GalloMF, NicholsMD, Continuous versus cyclic use of COC; a systematic Cochrane review of randomised controlled trials. Hum Reprod2006;21:573–8
9.
CoffeeAL, SulakP, KuehlT. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception2007;75:444–9
10.
FruzzettiF, BitzerJ. Review of clinical experience with estradiol in combined oral contraceptives. Contraception2010;81:8–15
11.
LopezLM, GrimesDA, GalloMF, SchulzKF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev2008:CD003552
12.
TimmerCJ, MuldersTM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet2000;39:233–42
13.
SulakPJ, CankaraN, MalasMA, KoyuncuE, DesdiciogluK. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomised controlled trial. Obstet Gynecol2008;112:563–71
14.
JuliatoCT, FernandesA, MarchiNM, Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception2007;76:282–6
15.
CurtisKM, MartinsSL. Progestogen-only contraception and BMD: a systematic review. Contraception2006;73:470–87
16.
KaunitzAM, AriasR, McClungM. Bone density recovery after DMPA injectable contraception use. Contraception2008;77:67–76
17.
GlasierAF, CameronST, FinePM, Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet2010;374:555–62
18.
Bodley-TickellAT, OlowokureB, BhaduriS, Trends in sexually transmitted infections (other than HIV) in older people: analysis of data from an enhanced surveillance system. Sex Transm Infect2008;84:312–17
19.
InkiP. Longterm use of the LNG IUS. Contraception2007;6(Suppl):S161–6
20.
JensenJT, NelsonAL, CostalesAC. Subject and clinician experience with the levonorgestrel-releasing IUS. Contraception2008;77:22–9
21.
HurskainenR, HoveSL, GisslerM, Hysteroscopic tubal sterilization: a systematic review of the Essure system. Fertil Steril2010DOI: 10.1016/j.fertnstert.2009.02.080
